PRIMARY STUDY
Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease
Key Findings: Azelnidipine showed significantly better renoprotection in hypertensive patients with mild chronic kidney disease (CKD) over amlodipine. This action is due to it's anti-oxidative effect resulting in lower urinary protein excretion, urinary 8-OHdG, and urinary L-FABP levels.
Type of Study: Clinical Trial
Study Sample Size: 30
Study Result: Positive
Research Location(s): Japan
Year of Pub: 2007
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
Citation: Nakamura T, et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci. 2007; 333:321-6. doi: 10.1097/MAJ.0b013e318065c254
Authors: Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K
